Statins - increasing or reducing the risk of Parkinson's disease?

Experimental Neurology

Volumn 228, Issue 1, 2011, Pages 1-4

  Dolga, Amalia M ^a   Culmsee, Carsten ^a   de Lau, Lonneke ^b   Winter, Yaroslav ^a   Oertel, Wolfgang H ^a   Luiten, Paul G M ^c   Eisel, Ulrich L M ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; ATORVASTATIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLESTEROL; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXYNITRITE; PITAVASTATIN; PLACEBO; PRAVASTATIN; PROTEIN KINASE B; PROTEIN P21; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UBIDECARENONE; UNINDEXED DRUG;

ANTIOXIDANT ACTIVITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CYTOKINE PRODUCTION; DIFFUSE LEWY BODY DISEASE; DISEASE MODEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSKINESIA; ENZYME ACTIVATION; ENZYME SYNTHESIS; HUMAN; ISCHEMIC HEART DISEASE; LIPID RAFT; MEDICAL RESEARCH; META ANALYSIS (TOPIC); METHODOLOGY; MITOCHONDRIAL RESPIRATION; MULTICENTER STUDY (TOPIC); MUSCLE RIGIDITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SAMPLE SIZE; SIGNAL TRANSDUCTION; TREMOR;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RISK FACTORS;

EID: 79851511554     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.11.013     Document Type: Note

References (37)

1. Bar-On P., Crews L., Koob A.O., Mizuno H., Adame A., Spencer B., Masliah E. Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J. Neurochem. 2008, 105:1656-1667.
2. Becker C., Jick S.S., Meier C.R. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf. 2008, 31:399-407.
3. Becker C., Meier C.R. Statins and the risk of Parkinson disease: an update on the controversy. Expert Opin. Drug Saf. 2009, 8:261-271.
4. Bieschke J., Zhang Q., Bosco D.A., Lerner R.A., Powers E.T., Wentworth P., Kelly J.W. Small molecule oxidation products trigger disease-associated protein misfolding. Acc. Chem. Res. 2006, 39:611-619.
5. Bosco D.A., Fowler D.M., Zhang Q., Nieva J., Powers E.T., Wentworth P., Lerner R.A., Kelly J.W. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrillization. Nat. Chem. Biol. 2006, 2:249-253.
6. de Lau L.M., Koudstaal P.J., Hofman A., Breteler M.M. Serum cholesterol levels and the risk of Parkinson's disease. Am. J. Epidemiol. 2006, 164:998-1002.
7. de Lau L.M., Stricker B.H., Breteler M.M. Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease. Mov. Disord. 2007, 22:1985.
8. Dolga A.M., Granic I., Nijholt I.M., Nyakas C., van der Zee E.A., Luiten P.G., Eisel U.L. Pretreatment with lovastatin prevents N-methyl-D-aspartate-induced neurodegeneration in the magnocellular nucleus basalis and behavioral dysfunction. J. Alzheimers Dis. 2009, 17:327-336.
9. Dolga A.M., Nijholt I.M., Ostroveanu A., Ten Bosch Q., Luiten P.G., Eisel U.L. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J. Alzheimers Dis. 2008, 13:111-122.
10. Folkers K., Langsjoen P., Willis R., Richardson P., Xia L.J., Ye C.Q., Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc. Natl Acad. Sci. USA 1990, 87:8931-8934.
11. Fortin D.L., Troyer M.D., Nakamura K., Kubo S., Anthony M.D., Edwards R.H. Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 2004, 24:6715-6723.
12. Ghosh A., Roy A., Matras J., Brahmachari S., Gendelman H.E., Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 2009, 29:13543-13556.
13. Hargreaves I.P., Lane A., Sleiman P.M. The coenzyme Q10 status of the brain regions of Parkinson's disease patients. Neurosci. Lett. 2008, 447:17-19.
14. Hernández-Romero M.C., Argüelles S., Villarán R.F., de Pablos R.M., Delgado-Cortés M.J., Santiago M., Herrera A.J., Cano J., Machado A. Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. J. Neurochem. 2008, 105:445-459.
15. Hu G., Antikainen R., Jousilahti P., Kivipelto M., Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology 2008, 70:1972-1979.
16. Huang X., Chen H., Miller W.C., Mailman R.B., Woodard J.L., Chen P.C., Xiang D., Murrow R.W., Wang Y.Z., Poole C. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov. Disord. 2007, 22:377-381.
17. Huang X., Abbott R.D., Petrovitch H., Mailman R.B., Ross G.W. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov. Disord. 2008, 23:1013-1018.
18. Koob A.O., Ubhi K., Paulsson J.F., Kelly J., Rockenstein E., Mante M., Adame A., Masliah E. Lovastatin ameliorates α-synuclein accumulation and oxidation in transgenic mouse models of α-synucleinopathies. Exp. Neurol. 2010, 221:267-274.
19. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003, 326:1423-1427.
20. Mena M.A., de Yebenes J.G. Drug-induced parkinsonism. Expert Opin. Drug Saf. 2006, 5:759-771.
21. Müller T., Kuhn W., Pohlau D., Przuntek H. Parkmsonism unmasked by Lovastatin. Ann. Neurol. 1995, 37:685-686.
22. Nassief A., Marsh J.D. Statin therapy for stroke prevention. Stroke 2008, 39:1042-1048.
23. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 1997, 100:2671-2679.
24. Ritz B., Manthripragada A.D., Qian L., Schernhammer E., Wermuth L., Olsen J., Friis S. Statin use and Parkinson's disease in Denmark. Mov. Disord. 2010, 25:1210-1216.
25. Samii A., Carleton B.C., Etminan M. Statin use and the risk of Parkinson disease: a nested case control study. J. Clin. Neurosci. 2008, 15:1272-1273.
26. Santiago M., Hernández-Romero M.C., Machado A., Cano J. Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+does not. Eur. J. Pharmacol. 2009, 609:58-64.
27. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., Kompoliti K., Perlmutter J.S., Reich S., Stern M., Watts R.L., Kurlan R., Molho E., Harrison M., Lew M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 2002, 59:1541-1550. Parkinson Study Group.
28. Schuster S., Nadjar A., Guo J.T., Li Q., Ittrich C., Hengerer B., Bezard E. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J. Neurosci. 2008, 28:4311-4316.
29. Selley M.L. Simvastatin prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res. 2005, 1037:1-6.
30. Sierra S., Ramos M.C., Molina P., Esteo C., Vazquez J.A., Burgos J.S. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis. 2010, 23:1-12.
31. Simon K.C., Chen H., Schwarzschild M., Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007, 69:1688-1695.
32. Van der Most P.J., Dolga A.M., Nijholt I.M., Luiten P.G., Eisel U.L. Statins: mechanisms of neuroprotection. Prog. Neurobiol. 2009, 88:64-75.
33. Wahner A.D., Bronstein J.M., Bordelon Y.M., Ritz B. Statin use and the risk of Parkinson disease. Neurology 2008, 70:1418-1422.
34. Wang Q., Tang X.N., Wang L., Yenari M.A., Ying W., Goh B.C., Lee H.S., Wilder-Smith E.P., Wong P.T. Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. Neurosci. Lett. 2006, 408:189-193.
35. Wang Q., Wang P.H., McLachlan C., Wong P.T. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res. 2005, 1045:229-233.
36. Wolozin B., Wang S.W., Li N.C., Lee A., Lee T.A., Kazis L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007, 5:20.
37. Yokoyama H., Yano R., Aoki E., Kato H., Araki T. Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice. Metab. Brain Dis. 2008, 23:335-349.